Document is current
Any future updates will be listed below
-
Authors
Shu, Daniel H.
Ho, Won Jin https://orcid.org/0000-0003-2644-5086
Kagohara, Luciane T. https://orcid.org/0000-0003-1706-0950
Girgis, Alexander https://orcid.org/0000-0002-4706-5480
Shin, Sarah M.
Danilova, Ludmila https://orcid.org/0000-0003-2813-3094
Lee, Jae W.
Sidiropoulos, Dimitrios N. https://orcid.org/0000-0001-5716-3917
Mitchell, Sarah
Munjal, Kabeer
Howe, Kathryn
Bendinelli, Kayla J. https://orcid.org/0000-0002-4072-9002
Kartalia, Emma
Qi, Hanfei https://orcid.org/0000-0002-0072-5752
Mo, Guanglan
Montagne, Janelle
Leatherman, James M.
Lopez-Vidal, Tamara Y.
Zhu, Qingfeng https://orcid.org/0000-0001-7871-3359
Huff, Amanda L.
Yuan, Xuan
Hernandez, Alexei https://orcid.org/0000-0002-6044-2631
Coyne, Erin M. https://orcid.org/0000-0002-0393-6600
Zaidi, Neeha https://orcid.org/0000-0002-0094-0049
Zabransky, Daniel J. https://orcid.org/0000-0002-8184-3346
Engle, Logan L. https://orcid.org/0000-0002-6375-9060
Ogurtsova, Aleksandra
Baretti, Marina
Laheru, Daniel
Durham, Jennifer N.
Wang, Hao
Sunshine, Joel C.
Johnston, Robert J.
Deutsch, Julie Stein
Taube, Janis M.
Anders, Robert A. https://orcid.org/0000-0002-2363-9072
Jaffee, Elizabeth M. https://orcid.org/0000-0003-3841-6549
Fertig, Elana J. https://orcid.org/0000-0003-3204-342X
Yarchoan, Mark https://orcid.org/0000-0003-4401-0748
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01CA253403)
Foundation for the National Institutes of Health (U01CA212007)
- License Information
-
More Information
Article History
Received: 12 October 2023
Accepted: 17 September 2024
First Online: 25 October 2024
Competing interests
: M.Y. reports consulting fees from Astra Zeneca, Exelixis, Genentech, Replimune, Hepion, Lantheus; research funding (to Johns Hopkins) from Bristol-Myers Squibb, Exelixis, Incyte and Genentech; and is a co-founder with equity of Adventris Pharmaceuticals. E.J.F. is on the Scientific Advisory Board of Viosera/Resistance Bio, is a paid consultant for Merck and Mestag Therapeutics, and receives research funds from Abbvie. W.J.H. has received patent royalties from Rodeo/Amgen and is the recipient of grants from Sanofi, NeoTX, and CirclePharma. He has received speaking/travel honoraria from Exelixis and Standard BioTools. E.M.J. reports grant/research support from the Lustgarten Foundation, Break Through Cancer, Roche/Genentech, Bristol-Meyers Squibb; honoraria from Achilles, DragonFly, Parker Institute, Cancer Prevention and Research Institute of Texas, Surge, HDT Bio, Mestag Therapeutics, Medical Home Group; and equity in AbMeta Therapeutics and Adventris Pharmaceuticals. D.J.Z. reports grant/research support from Roche/Genentech. R.J.J. is an employee and stockholder of Roche/Genentech. J.M.T. reports research funding from BMS and Akoya Biosciences; serves as a consultant for BMS, Merck, Astra Zeneca, Genentech, Regeneron, Elephas, Lunaphore, Compugen, and Akoya Biosciences; and holds stock in Akoya Biosciences. The remaining authors declare no competing interests.
